29 September 2020: Sysmex Applies for Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent – Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800
01 June 2020: Sysmex and OPTiM Jointly Establish New Company to Plan, Develop and Operate Medical AI and IoT Open Platforms and Digital Transformation Solutions
25 May 2020: Sysmex Donates ¥30 Million to Kobe City Support Fund for Medical Professionals to Support COVID-19 Countermeasures
18 May 2020: The City of Kobe, Sysmex and SRL Configure and Begin Operating a PCR Testing System for COVID-19 within the Kobe Biomedical Innovation Cluster
11 May 2020: Sysmex New Zealand and ESR collaborate on national COVID-19 results CDR

Within hours of New Zealand lifting to alert level 4, a collaborative project was initiated between the Institute of Environmental Science and Research (ESR) and Sysmex New Zealand to establish a national clinical data repository (CDR) for all COVID-19 test reports from testing lab facilities across the country.   ESR provide an extensive range of […]

27 March 2020: Sysmex Obtains First Marketing Approval in Japan for the Novel Coronavirus Nucleic Acid Detection Kits (RT-PCR Method) – Aiming for early introduction of test kits for in vitro diagnostic medical devices in medical institutions –
31 January 2020: Sysmex Invests in Astrego Diagnostics with a View to Developing New Urinalysis Solutions for the Primary Care Business